Arrowhead Pharmaceuticals Inc (ARWR)

INDUSTRIALS: COMMERCIAL SERVICES & SUPPLIES
SIC: PHARMACEUTICAL PREPARATIONS

177 E COLORADO BLVD PASADENA, CA 91105

Arrowhead Research seeks to commercialize pioneering, breakthrough products in nanotechnology by forming or acquiring subsidiary companies; by funding nanoscience research at universities; and through the acquisition, license and sublicense of intellectual property in the field of nanotechnology.

Data as of 2020-09-12
Market Cap3.397 Billion Shares Outstanding102.292 Million Avg 30-day Volume943.706 Thousand
P/E Ratio Dividend Yield EPS-0.25
Price/Sales27.473 Price cash flow ratio23.9 Price free cash flow ratio-40.6
Book Value4.82 Price to Tangible Book7.3 Alpha0.06
Short Interest Ratio % Short Interest to Float R-squared0.067009
BETA1.65455 52-week High/Low73.72 / 19.5101 Stddev0.2731
View SEC Filings from ARWR instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 3 2 50.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 249 240 3.75% 57 (3.72%) 56 (3.58%) 1.79%
13F shares: 67.841 Million 65.319 Million 3.86% 13.684 Million 13.87 Million -1.34%
% Ownership 66.3214 64.2556 3.21% 13.3774 13.6439 -1.95%
New Positions: 42 34 23.53% 14 12 16.67%
Increased Positions 95 88 7.95% 19 22 -13.64%
Closed Positions 32 81 -60.49% 13 29 -55.17%
Reduced Positions 74 90 -17.78% 19 18 5.56%
Total Calls 1.258 Million 873.507 Thousand 44.03% 345.4 Thousand 207.7 Thousand 66.3%
Total Puts 782.292 Thousand 837.014 Thousand -6.54% 235.2 Thousand 178.8 Thousand 31.54%
PUT/CALL Ratio 0.62 0.96 -35.42% 0.68 0.86 -20.93%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ARWR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARWR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

50 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

50 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

OLUKOTUN ADEOYE Y

  • Director
5,000 2020-09-01 1

ANZALONE CHRISTOPHER RICHARD CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
2,605,237 2020-08-13 7

PERRY MICHAEL S

  • Director
85,000 2020-05-14 3

WADDILL WILLIAM D.

  • Director
28,000 2020-05-11 2

GIVEN BRUCE D CHIEF OPERATING OFFICER

  • Officer
850,730 2020-04-27 4

GIVEN DOUGLAS B

  • Director
154,813 2020-04-14 2

MYSZKOWSKI KENNETH ALLEN CHIEF FINANCIAL OFFICER

  • Officer
427,668 2020-02-25 6

FERRARI MAURO

  • Director
40,971 2020-02-17 2

DE BACKER MARIANNE

  • Director
16,500 2020-01-13 3

O'BRIEN PATRICK GENERAL COUNSEL

  • Officer
258,375 2020-01-06 2

HASSARD JAMES CHIEF COMMERCIAL OFFICER

  • Officer
125,000 2020-01-06 1

BRADSHAW CURT CHIEF SCIENTIFIC OFFICER

  • Officer
125,000 2019-11-18 1

SAN MARTIN JAVIER CHIEF MEDICAL OFFICER

  • Officer
150,000 2019-11-18 1

LI ZHEN SNR. VP, CHEM AND NON-CLIN DEV

  • Officer
201,700 2019-01-14 0

LEONE PETER BRIAN VP, STRATEGIC BUS. INITIATIVES

  • Officer
130,000 2018-10-19 0

FRYKMAN EDWARD W

  • Director
148,852 2018-01-01 0

LEWIS DAVID L. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-01-01 0

MCKENNEY CHARLES

  • Director
42,220 2015-03-04 0

RAHN LEROY T

  • Director
0 2010-03-04 0

STEWART R BRUCE EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2010-03-04 0

MCDONNEL PAUL CLAYTON CFO (FORMER)

  • Officer
No longer subject to file 2009-07-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

ANZALONE CHRISTOPHER RICHARD - Director - Officer CHIEF EXECUTIVE OFFICER

2020-08-14 18:08:19 -0400 2020-08-13 M 50,000 $9.90 a 2,655,237 direct

ANZALONE CHRISTOPHER RICHARD - Director - Officer CHIEF EXECUTIVE OFFICER

2020-08-14 18:08:19 -0400 2020-08-13 M 50,000 d 895,543 direct

ANZALONE CHRISTOPHER RICHARD - Director - Officer CHIEF EXECUTIVE OFFICER

2020-08-14 18:08:19 -0400 2020-08-13 S 50,000 $41.35 d 2,605,237 direct yes

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments